MAPT and Alzheimer disease: In this study, we demonstrated for the first time that clinical doses of sevoflurane can aggravate AD progression by inducing pyroptosis and tau pathology via a novel mechanism involving the activation of the NLRP3/ASC/caspase-1 pathway.